Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination
Corbett T. Berry, Mouhanned Eliliwi, Stefanie Gallagher, Sophia Panaccione, Walter M. Klein, Andrea L. Healy, Brian Stoecker, Romy Kallas
Abstract
Two single-dose COVID-19 vaccines utilizing the adenoviral vector platform, ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen), have recently been associated with rare immune-mediated thrombotic events and thrombocytopenia.1-3 In response to 6 reports on Ad26.COV2.S-associated thrombosis, the US Food and Drug Administration recommended a brief pause in the use of the Ad26.COV2.S vaccine on April 13, 2021. After further investigation, the US Food and Drug Administration and Centers for Disease Control and Prevention concluded that the vaccine's benefits outweigh the low risk of thrombosis and recommended the resumption of Ad26.COV2.S vaccination with a manufacturer warning for possible thrombosis.